Eosinophilic Esophagitis Pipeline Review Report, H2 2020 – Therapeutic Analysis of 20 Companies & Drug Profiles – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Eosinophilic Esophagitis – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Eosinophilic Esophagitis – Pipeline Review, H2 2020, provides an overview of the Eosinophilic Esophagitis (Gastrointestinal) pipeline landscape.

Eosinophilic esophagitis is disease characterized by the presence of a large number of a special type of white blood cell, the eosinophil that can cause inflammation in the esophagus. Symptoms include poor weight gain, abdominal pain, nausea, and vomiting, coughing, heartburn and chest pain. Risk factors include weakened immune system, chemotherapy, aspirin and anti-inflammatory medications, chronic vomiting, obesity and alcohol and cigarette use. Treatment includes antiviral, antifungal and pain relievers.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Eosinophilic Esophagitis – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Eosinophilic Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Eosinophilic Esophagitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 5, 3, 3 and 9 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Eosinophilic Esophagitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

• Introduction
• Eosinophilic Esophagitis – Overview
• Eosinophilic Esophagitis – Therapeutics Development
• Eosinophilic Esophagitis – Therapeutics Assessment
• Eosinophilic Esophagitis – Companies Involved in Therapeutics Development
• Eosinophilic Esophagitis – Drug Profiles
• Eosinophilic Esophagitis – Dormant Projects
• Eosinophilic Esophagitis – Discontinued Products
• Eosinophilic Esophagitis – Product Development Milestones
• Appendix

Companies Mentioned

• Adare Pharma Solutions
• Allakos Inc
• Arena Pharmaceuticals Inc
• Banner Life Sciences LLC
• Bristol-Myers Squibb Co
• Calypso Biotech SA
• DBV Technologies SA
• Dr. Falk Pharma GmbH
• Ellodi Pharmaceuticals
• EsoCap AG
• GlaxoSmithKline Plc
• Humanigen Inc
• Kyowa Kirin Co Ltd
• Landos Biopharma Inc
• Morphic Holding Inc
• Quorum Innovations LLC
• RAPT Therapeutics Inc
• Regeneron Pharmaceuticals Inc
• Suzhou Connect Biopharmaceuticals Ltd
• Takeda Pharmaceutical Co Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/t4ee3q

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900